Browse the evidence

Men experience greater magnitude of weight loss and cardiometabolic improvement (insulin sensitivity, lipids) from low-calorie diets than women, but women maintain these benefits better during weight maintenance due to lower metabolic rebound.

If you are a woman, expect your initial weight loss on a strict low-calorie diet to be slower than a man's, but recognize that your body may be better at keeping your blood fats and insulin sensitivity stable once you stop dieting. Focus on the long-term maintenance of health markers rather than just the scale number during the first 8 weeks.

Intermittent fasting (IMF) and daily caloric restriction (DCR) produce equivalent weight loss when matched for energy deficit and delivered with guideline-based behavioral support and physical activity prescriptions.

To lose weight effectively, you can choose either daily calorie restriction or intermittent fasting, but the key is consistency and support. Ensure your total weekly energy deficit is similar regardless of the method. Crucially, engage in a structured behavioral support program that includes regular check-ins, goal setting, and physical activity (aiming for 300 minutes of moderate exercise per week). This structured approach is more important than the specific timing of your meals for long-term success.

Combination therapy with half-dose rosiglitazone and metformin significantly reduces the incidence of type 2 diabetes in patients with impaired glucose tolerance compared to placebo.

If you have impaired glucose tolerance, combining half-dose rosiglitazone (2mg) and metformin (500mg) twice daily significantly reduces your risk of developing type 2 diabetes (66% relative risk reduction) compared to placebo. This regimen is effective and appears safe with few side effects.

Ad libitum low-carbohydrate diets promote weight loss without significant fat mass reduction, whereas ad libitum low-fat diets promote significant fat mass loss, indicating that early weight loss on low-carb diets does not necessarily reflect negative energy balance or fat loss.

If your goal is fat loss, a low-fat diet may be more effective than a low-carb diet when eating ad libitum, as low-carb diets may result in weight loss driven by water and glycogen depletion rather than fat loss. Focus on body composition changes (like DEXA scans or progress photos) rather than just scale weight when starting a low-carb diet.

There is no significant difference in the reduction of absolute fat mass (kg) or waist circumference between low-carbohydrate and low-fat diets.

While LCDs may lower BMI and body fat percentage more than LFDs, they do not necessarily reduce absolute fat mass (kg) or waist circumference more effectively. If waist circumference is your primary goal, either diet may be equally effective.

Semaglutide treatment is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) compared to placebo, though these are mostly mild to moderate.

Be prepared for gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but usually mild and temporary. Titration helps manage them.

High body mass index (BMI) is a causal risk factor for a broad spectrum of chronic diseases, including cardiovascular disease, diabetes, chronic kidney disease, multiple cancers, and musculoskeletal disorders, resulting in significant global mortality and disease burden.

Maintaining a BMI within the 20-25 kg/m2 range is associated with the lowest all-cause mortality risk. This is not just about weight but about reducing the risk of major chronic diseases like heart disease, diabetes, and certain cancers. Public health surveillance and evidence-based interventions are critical to addressing this growing burden.

A significant portion of deaths related to high BMI occur among individuals who are not clinically obese (BMI < 30 kg/m2), indicating that overweight status (BMI 25-29.9) also carries substantial mortality risk.

You do not need to be obese to face increased health risks. Being overweight (BMI 25-29.9) accounts for a large portion of deaths related to high body weight. Aim for a BMI in the 20-25 range to minimize mortality risk.

Cardiovascular disease is the primary cause of death associated with high BMI, accounting for more than two-thirds of high-BMI-related deaths.

Heart disease is the biggest killer linked to high body weight. Keeping your BMI in the 20-25 range is one of the most effective ways to protect your heart.

Higher body-mass index (BMI) is associated with significantly increased mortality rates from all cancers combined and from multiple specific cancer sites, with the highest risks observed in individuals with a BMI of 40 or greater.

Maintaining a BMI in the normal range (18.5-24.9) is one of the most effective ways to reduce your risk of dying from cancer. The risk of cancer death increases steadily as BMI increases, with those having a BMI of 40 or higher facing more than a 50% higher risk of cancer death compared to those of normal weight. This applies to both men and women and covers many specific cancer types.

Overweight and obesity account for a substantial proportion of cancer deaths in the U.S. population, estimated at 14% for men and 20% for women.

Maintaining a healthy weight is a powerful tool for cancer prevention. This study estimates that 14% of cancer deaths in men and 20% in women are attributable to being overweight or obese. By keeping your BMI under 25, you can significantly reduce your risk of dying from cancer.

Liraglutide (a GLP-1 receptor agonist) significantly reduces the risk of major adverse cardiovascular events (MACE) and cardiovascular death in patients with type 2 diabetes and high cardiovascular risk.

If you have type 2 diabetes and are at high risk for heart problems (like existing heart disease or multiple risk factors), adding liraglutide to your standard care can significantly lower your risk of heart attack, stroke, and death from cardiovascular causes. It is taken as a daily injection. While it can cause stomach issues, the cardiovascular benefits are substantial for this high-risk group.

Once-weekly subcutaneous semaglutide (0.5 mg or 1.0 mg) significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high cardiovascular risk, demonstrating both noninferiority and superiority over placebo.

If you have type 2 diabetes and are at high risk for heart problems, once-weekly semaglutide injections can significantly lower your risk of heart attack, stroke, or cardiovascular death compared to placebo. The treatment involves a gradual dose increase to minimize side effects like nausea, which are common but usually mild and temporary. The cardiovascular benefits are substantial and well-supported by a large, rigorous clinical trial.

A targeted, long-term, intensified multifactorial intervention (targeting hyperglycemia, hypertension, dyslipidemia, and microalbuminuria via behavior modification and pharmacotherapy) reduces the risk of cardiovascular and microvascular events by approximately 50% in patients with type 2 diabetes and microalbuminuria compared to conventional treatment.

If you have type 2 diabetes and early kidney warning signs (microalbuminuria), standard care may not be enough to protect your heart and kidneys. This study shows that a rigorous, long-term plan targeting blood sugar, blood pressure, cholesterol, and kidney health simultaneously—supported by frequent check-ins and lifestyle changes—can cut your risk of serious heart and kidney problems by half. It requires commitment to diet, exercise, and medications, but the long-term benefit is substantial.

Obesity (BMI ≥30) significantly increases the risk of developing depression over time, with a pooled odds ratio of 1.55, and this association is stronger in American populations and for clinical diagnoses compared to depressive symptoms.

If you have obesity, be aware that it may increase your risk of developing depression, particularly if you are in a culture with strong thinness ideals (like the US). This risk is mediated by biological factors like inflammation and stress hormones, as well as psychological factors like body dissatisfaction. Treating obesity may help reduce depression risk, and treating depression may help manage weight, suggesting a bidirectional approach to care is beneficial.

Depression (symptoms or disorder) significantly increases the risk of developing obesity (BMI ≥30) over time, with a pooled odds ratio of 1.58, but does not significantly increase the risk of developing overweight (BMI 25-29.99).

If you have depression, be aware that it may increase your risk of developing obesity, especially if your depression is long-standing (≥10 years). This risk is driven by biological factors like stress hormones and lifestyle changes. Treating depression effectively may help prevent obesity, and managing weight may help alleviate depression, suggesting a bidirectional approach to care is beneficial.

Waist circumference (WC) is a superior predictor for certain co-morbidities (diabetes, hypertension, coronary artery disease, stroke, gallbladder disease) compared to Body Mass Index (BMI) alone.

Don't just rely on the scale. Measuring your waist circumference provides a more accurate picture of your health risk for heart disease and diabetes than BMI alone. If you have excess weight around your midsection, your risk is higher, even if your BMI is in the 'overweight' rather than 'obese' range.

Obesity is associated with a significantly higher incidence of endometrial cancer compared to normal weight, with a relative risk of 3.22 for obese women.

For women, maintaining a healthy weight is particularly important for reducing the risk of endometrial cancer. Obesity more than triples the risk compared to normal weight. Weight management is a key preventive strategy.

For healthy, never-smoking adults, the optimal body-mass index (BMI) for longevity is 23.5–24.9 for men and 22.0–23.4 for women, with mortality risk increasing linearly as BMI rises above these ranges.

If you are a healthy adult who has never smoked, aim for a BMI between 23.5 and 24.9 (men) or 22.0 and 23.4 (women) to minimize mortality risk. Avoiding overweight and obesity is critical for longevity, regardless of age, as higher BMI consistently increases absolute death risk.

Obesity acts as an independent risk factor for cardiovascular disease (CVD) and increases morbidity and mortality through multiple mechanisms, including metabolic alterations, cardiac structural changes, and hemodynamic stress, even in the absence of traditional comorbidities.

Obesity is not just a cosmetic issue or a marker for other diseases; it actively damages the heart's structure and function. Maintaining a healthy weight is one of the most effective ways to reduce your risk of heart disease, heart failure, and stroke, regardless of your cholesterol or blood pressure levels.

Obesity is associated with metabolic syndrome, which significantly increases the risk of cardiovascular disease and mortality, independent of diabetes status.

Metabolic Syndrome is a serious condition that increases your risk of heart disease and death, even if you don't have diabetes. It involves high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels. Addressing all these factors is crucial for heart health.

Chronically restricting sleep to 6 hours or less per night for 14 consecutive days produces cumulative cognitive performance deficits equivalent to 1-2 nights of total sleep deprivation, despite subjects remaining largely unaware of their declining performance.

If you consistently sleep 6 hours or less, your cognitive performance (reaction time, memory, decision-making) will degrade daily over two weeks to the level of someone who has been awake for 48 hours. You will not feel this decline because your subjective sense of sleepiness plateaus early. To maintain peak cognitive function, you must prioritize 7-8 hours of sleep, as 'getting used to' less sleep is a dangerous illusion that impairs your performance without your awareness.

Insulin resistance is a multisystem disorder that predisposes individuals to both cardiovascular disease and type 2 diabetes, often manifesting as the metabolic syndrome (abdominal obesity, atherogenic dyslipidemia, hypertension, glucose intolerance, and prothrombotic state).

If you have high blood pressure, high cholesterol, and high blood sugar, you likely have insulin resistance. This cluster of conditions, called the metabolic syndrome, significantly increases your heart disease risk. The most effective strategy is to address the root cause: improve your insulin sensitivity through weight loss, physical activity, and dietary changes, rather than just managing each number in isolation.

Aggressive LDL-lowering therapy reduces recurrent coronary heart disease (CHD) events in patients with diabetes, even if their baseline LDL cholesterol is not markedly elevated.

If you have diabetes and heart disease, you likely need a statin even if your LDL cholesterol isn't extremely high. Clinical trials show that aggressive LDL lowering significantly reduces the risk of future heart attacks in diabetics. Aim for an LDL level below 100 mg/dL through medication and diet, as your blood vessels are more susceptible to damage from LDL.